4CPS-151 Influence of the route and pharmaceutical preparation in intra-patient variability of tacrolimus serum levels in the liver transplant patient

BackgroundIn the earliest stages, immunosuppressive therapy in liver transplant patients (LTP) is targeted to avoid acute rejection, to preserve graft survival and to minimise the risk of pharmacological adverse reactions. The use of different administration routes or immediate-prolonged release pre...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2019-03, Vol.26 (Suppl 1), p.A139-A140
Main Authors: Garcia Garcia, S, Dopazo Taboada, C, Aller Hernández, MB, Bilbao Aguirre, I, Pericas Bosch, E, Montoro Ronsano, JB
Format: Article
Language:English
Subjects:
Liver
Liver transplants
Patients
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundIn the earliest stages, immunosuppressive therapy in liver transplant patients (LTP) is targeted to avoid acute rejection, to preserve graft survival and to minimise the risk of pharmacological adverse reactions. The use of different administration routes or immediate-prolonged release preparations could influence tacrolimus serum levels (FKs) and variability.PurposeTo assess the mean concentration and the intra-patient variability (IPV) of FKs after their administration through immediate-prolonged release preparations and/or different administration routes in LTP.Material and methodsObservational retrospective study including LTP within 2015–2017.Clinical data was collected from the hospital’s medical records, including: type of transplant, date of surgery, tacrolimus pharmaceutical form (TacPP), administration route and FKs values within 1 month after liver transplant.FKs mean levels, coefficient of variation (CV), proportion of patients with CV >30% (CV30) and proportion of FKs values lower than 5 ng/mL (P5) per patient were calculated. The influence of the TacPP administered (immediate/prolonged/extended release) and the administration route (oral/nasogastric tube), in case of immediate-release tacrolimus form was also analysed.Therapeutic control was considered inadequate if CV30 occurred, or P5 was higher than 20%.Statistical analysis was done using SPSS. Variance analysis and the Krukal–Wallis test were used to compare quantitative variables.ResultsEighty-four patients were included. The values of the variables analysed – mean FKs, P5 and CV30 observed – were 8.0 ng/mL (SD, 4.2), 19.3% (SD, 39.6) and 66.0% (DE, 46.9). Technically, 68.3% patients had poor FKs control levels.According to TacPP, values for mean FKs, P5 and CV30 observed were:Immediate-release tacrolimus: 8.5 ng/mL (95% CI: 6.2 to 10.9), 28.6% (–95% CI: 12.8 to 44.3) and 58.1% (95% CI: 39.7 to 76.5).Prolonged-release tacrolimus: 7.9 ng/mL (95% CI: 6.2 to 10.9), 10.5% (95% CI: 1.0 to 25.6) and 66.7% (95% CI: 55.0 to 78.3).Extended-release tacrolimus: 9.6 ng/mL (95% CI: 8.0 to 11.3), 8.3% (95% CI: 0.0 to 27.0) and 83.3% (95% CI: 58.6 to 100.0).According to the administration route (immediate-release tacrolimus form), values for mean FKs, P5 and CV30 observed were:Oral: 8.5 ng/mL (95% CI: 6.2 to 10.9), 28.6% (95% CI: 6.7 to 24.9) and 58.1% (95% CI: 40.0 to 76.5).Nasogastric tube: 6.8 ng/mL (95% CI: 5.5 to 8.0), 32.3% (95% CI: 14.8 to 49.7) and 76.0% (95% CI: 58.0 to 94.0).Mean FK
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2019-eahpconf.300